GSK Egypt considers merge of Amoun Pharmaceutical Industries

The board of directors of Glaxo SmithKline (GSK Egypt) decided to form a committee to study the merge of Amoun Pharmaceutical Industries into the company.

The board also approved to refer the decision of the appointment of independent board members to the shareholders for approval, according to a bourse disclosure on Thursday.

Ashraf Mansour was named the company’s Chairman, as a representative of Glaxo Group Ltd, and Henry Antaki was appointed as Managing Director, as a representative of Glaxo Group Ltd.

Earlier in December, the company denied news reports about the acquisition of its subsidiary Amoun Pharmaceutical Industries